DOI: 10.1097/01.qai.0000351181.61412.42
,
Issn Print: 1525-4135
Publication Date: 2009/06/01
225 New Viral and Tuberculosis Therapeutics for the 21st Century
Excerpt
There remains high medical need in various area of virology and drug treatment of resistant tuberculosis. Tibotec has worked for the last decade in developing novel anti-retroviral drugs including Prezista and Intelence to combat resistant HIV-1 infections, and treat patients with simple and effective regimens during initial naïve treatment (eg. TMC278). We are now also looking at important co-travelers with HIV including Hepatitis C virus with the use of new protease inhibitors (VX-950 and TMC435). Finally, a novel anti-tuberculosis compound TMC207 using a new mechanism of action, ATP synthase inhibition, is being developed initially for MDR tuberculosis. As such, this portfolio of compounds will be critical in treating these viral and mycobacterial pandemics in both the developed and developing world.
Facebook
Twitter
LinkedIn
Email
